Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally

Alkem Laboratories

Alkem Laboratories share price down marginally in the opening trade on March 23 despite the company received DCGI approval to manufacture and market Semaglutide Injection in India.

At 09:21am, Alkem Laboratories was quoting at Rs 5,204.05, down Rs 53.70, or 1.02 percent, on the BSE.

The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450.

Apart from disposable pen, Alkem is offering reusable injection pen for semaglutide administration for higher maintenance doses.

Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, subsequent to a review of its Phase 3 clinical trials conducted in India.

The company launched semaglutide injection in India under the brand names “Semasize”, Obesema” and “Hepaglide”.

Catch all the market action on our live blog

The company has received a ‘Certificate of GMP Compliance of a Manufacturer’ from the Malta Medicines Authority for its manufacturing facility located at Daman, India.

The said certificate is valid for a period of three years from December 9, 2025.

Also, earlier in this month, the Department of Pharmacy (Human Medicines) – Germany has issued 'Certificate of GMP Compliance of a Manufacturer’ to company's manufacturing facility located at Baddi, India, which valid for a period of three years from.